Advertisement
CGEN vs KLRS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a Hold and KLRS is a Hold.
Momentum Indicator for CGEN turns positive, indicating new upward trend
CGEN saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 69 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CGEN's RSI Indicator exited the oversold zone, 35 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for CGEN just turned positive on October 28, 2026. Looking at past instances where CGEN's MACD turned positive, the stock continued to rise in 39 of 50 cases over the following month. The odds of a continued upward trend are 78%.
Following a +11.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGEN advanced for three days, in 187 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 50-day moving average for CGEN moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
CGEN broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CGEN entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 20 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. CGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.092) is normal, around the industry mean (3.498). P/E Ratio (5.158) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.083) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
KLRS's Stochastic Oscillator descends into oversold zone
The Stochastic Oscillator for KLRS moved into oversold territory on November 11, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KLRS's RSI Indicator exited the oversold zone, 33 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for KLRS just turned positive on October 28, 2026. Looking at past instances where KLRS's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
Following a +19.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where KLRS advanced for three days, in 197 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KLRS as a result. In 90 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KLRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KLRS broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KLRS entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.999) is normal, around the industry mean (3.498). P/E Ratio (-1.277) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. KLRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KLRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CGEN | KLRS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 38 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 41 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 20 | 98 | |
PRICE GROWTH RATING 1..100 | 60 | 88 | |
P/E GROWTH RATING 1..100 | 57 | 12 | |
SEASONALITY SCORE 1..100 | 42 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KLRS's Valuation (41) in the null industry is somewhat better than the same rating for CGEN (76) in the Biotechnology industry. This means that KLRS’s stock grew somewhat faster than CGEN’s over the last 12 months.
KLRS's Profit vs Risk Rating (100) in the null industry is in the same range as CGEN (100) in the Biotechnology industry. This means that KLRS’s stock grew similarly to CGEN’s over the last 12 months.
CGEN's SMR Rating (20) in the Biotechnology industry is significantly better than the same rating for KLRS (98) in the null industry. This means that CGEN’s stock grew significantly faster than KLRS’s over the last 12 months.
CGEN's Price Growth Rating (60) in the Biotechnology industry is in the same range as KLRS (88) in the null industry. This means that CGEN’s stock grew similarly to KLRS’s over the last 12 months.
KLRS's P/E Growth Rating (12) in the null industry is somewhat better than the same rating for CGEN (57) in the Biotechnology industry. This means that KLRS’s stock grew somewhat faster than CGEN’s over the last 12 months.
| CGEN | KLRS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 81% | 1 day ago 80% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 89% |
| Momentum ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 78% | 1 day ago 83% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 79% | 1 day ago 90% |
| Advances ODDS (%) | 3 days ago 81% | 6 days ago 85% |
| Declines ODDS (%) | 17 days ago 88% | 2 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CGEN’s FA Score shows that 1 FA rating(s) are green while KLRS’s FA Score has 1 green FA rating(s).
- CGEN’s FA Score: 1 green, 4 red.
- KLRS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CGEN’s TA Score shows that 4 TA indicator(s) are bullish while KLRS’s TA Score has 4 bullish TA indicator(s).
- CGEN’s TA Score: 4 bullish, 5 bearish.
- KLRS’s TA Score: 4 bullish, 4 bearish.
Price Growth
CGEN (@Biotechnology) experienced а +2.96% price change this week, while KLRS (@Biotechnology) price change was -5.94% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
CGEN is expected to report earnings on Mar 09, 2027.
KLRS is expected to report earnings on Mar 23, 2027.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with RXRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then RXRX could also see price increases.
| Ticker / NAME | Correlation To CGEN | 1D Price Change % | ||
|---|---|---|---|---|
| CGEN | 100% | N/A | ||
| RXRX - CGEN | 39% Loosely correlated | +1.13% | ||
| RCUS - CGEN | 37% Loosely correlated | +0.70% | ||
| ABCL - CGEN | 37% Loosely correlated | -4.09% | ||
| AXON - CGEN | 36% Loosely correlated | +4.26% | ||
| GHRS - CGEN | 36% Loosely correlated | -1.58% | ||
More | ||||
KLRS and
Correlation & Price change
A.I.dvisor indicates that over the last year, KLRS has been loosely correlated with PTHS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KLRS jumps, then PTHS could also see price increases.
| Ticker / NAME | Correlation To KLRS | 1D Price Change % | ||
|---|---|---|---|---|
| KLRS | 100% | +1.60% | ||
| PTHS - KLRS | 43% Loosely correlated | +5.51% | ||
| CGEN - KLRS | 29% Poorly correlated | N/A | ||
| CAMP - KLRS | 28% Poorly correlated | -3.00% | ||
| MESO - KLRS | 27% Poorly correlated | -2.43% | ||
| RCKT - KLRS | 26% Poorly correlated | +1.22% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SEA | 20.06 | 0.43 | +2.19% |
| U.S. Global Sea to Sky Cargo ETF (SEA) | |||
| FDCF | 50.83 | 0.48 | +0.96% |
| Fidelity Disruptive Communications ETF (FDCF) | |||
| XLFX | 30.60 | N/A | N/A |
| Corgi U.S. Financials 2x Daily ETF (XLFX) | |||
| HFSI | 33.89 | -0.02 | -0.06% |
| Hartford Strategic Income ETF (HFSI) | |||
| RSPD | 58.06 | -0.18 | -0.31% |
| Invesco S&P 500 Equal Weight Consumer Discretionary ETF (RSPD) | |||